Bristol Likes What It Sees In Five Prime, Invests More In CSF1R Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol agreed to pay $350m upfront for global rights to Five Prime’s CSF1R antibody program, including FPA008, in a deal that builds on the companies’ previous clinical collaboration agreement.
You may also be interested in...
Biopharma Quarterly Dealmaking Statistics, Q4 2015
Biopharma financing for Q4 totaled $13.1 billion, a 35% increase over Q3, and again was dominated by follow-on public offerings. M&A reached a record $201 billion, topped by Pfizer's $160 billion buy of Allergan. Sanofi's $4.2 billion diabetes collaboration with Hanmi led the alliances.
How To Catch The Next Wave Of Cancer Immunotherapy
Forging a development partnership with a big pharma PD-1/L1 sponsor has become a sort of beauty contest with many in the running, and small companies are best advised to invest in good preclinical datasets to make the grade, execs say at the BIO Investor Forum in San Francisco.
Deal Watch: Bristol Doubles Down On Five Prime, Roche Continues Diversifying
Roche buyout of California biotech Adheron will strengthen its pipeline in rheumatoid arthritis and fibrosis. Lilly keeps busy, expanding an immuno-oncology collaboration with China's Innovent and acquiring a Phase III intranasal hypoglycemia candidate from Locemia.